| Title | Increased prevalence of chlamydia pneumoniae antibodies and restenosis of coronary arteries after Percutaneous Transluminal Coronary Angioplasty (PTCA) | |
| Authors | Rengina Vorou1, Vassilios Papavassiliou1, Vassiliki Petrocheilou-Paschou2, Marlena Alexandrou2 and John Kanakakis2
1. Consultant in Hellenic Center for Diseases Control and Prevention (H.C.D.C.P.), Athens, Hellas 2. Department of Clinical Therapeutics, Alexandra Hospital, Medical school, National and Kapodistrian University of Athens, Athens, Hellas |
|
| Citation | Vorou, R., Papavassiliou, V., Petrocheilou-Paschou, V., Alexandrou, M. and Kanakakis, J.: Increased prevalence of chlamydia pneumoniae antibodies and restenosis of coronary arteries after Percutaneous Transluminal Coronary Angioplasty (PTCA), Epitheorese Klin. Farmakol. Farmakokinet. 23(3): 147-152 (2009) | |
| Publication Date | Accepted for publication (Final Version): July 1, 2009 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Coronary disease, angioplasty, restenosis, chlamydia pneumoniae. | |
| Other Terms | review article | |
| Summary | This prospective study in a series of 110 Greek patients the Greek population investigates the incidence of elevated antibody titers against Chlamydia pneumoniae (Cp) and their association with restenosis, within the first semester after Percutaneous Transluminal Coronary Angioplasty (PTCA). IgG, IgA and IgM antibodies against Chlamydia pneumoniae were measured at the time of PTCA and 6 months later, when the patients were examined for restenosis. In the microimmunofluorescence method used, elementary bodies of TWAR-183 Chlamydia pneumoniae served as antigen. Seventy seven patients were found with persisting seropositivity anti-Cp IgG>1/40 and 27 patients with persisting seropositivity anti-Cp IgA>1/40. IgM was found in all tests negative and IgG≤1/320, consequently none of our patients suffered from acute chlamydial infection. Six months after PTCA all patients underwent exercise test with myocardium perfusion imaging (MPI) with TL201, and when this was positive an angiogram, and if indicated a new angioplasty were performed. In the multiple logistic regression analysis patients with restenosis had 3.57 times (OR=3.57) more frequently elevated titres regarding IgG>1/40 (P=0.06) and 3.63 times (OR=3.63) more frequently regarding IgA>1/40 (P=0.03) than patients without restenosis. These findings indicate that elevated IgG and IgA antibodies against Cp could be prognostic factors for restenosis of coronary arteries post PTCA and support further studies to clarify this association. | |
| References | 1. Serruys P.W., Luijten H.E., Beatt K.J., Serruys P.W., Luijten H.E., Beatt K.J., Geuskens R., de Feyter P.J., van den Brand M., Reiber J.H., ten Katen H.J., van Es G.A., Hugenholtz P.G.: Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3 and 4 months. Circulation 77: 361-371 (1998)
2. Hirshfeld J.W.,Jr, Schwartz J.S., Jugo R., MacDonald R.G., Goldberg S., Savage M.P., Bass T.A., Vetrovec G., Cowley M., Taussig A.S., et al.: Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. J. Am. Coll. Cardiol. 18: 647-656 (1991) 3. Multiple Risk Factor Intervention Trial Research Group: Mortality rates after 10.5 years for participants in the multiple risk factor intervention trial. Findings related to a priori hypothesis of the trial. J. Am. Med. Assoc. 263: 1795-1801 (1990) 4. Mattila K.J., Valtonen V.V., Nieminen M.S., Asikainen S.: Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin. Infect. Dis. 26: 719-734 (1998) 5. Saikku P., Leinonen M., Tenkanen L., Linnanmaki E., Ekaman M.R., Manninen V.: Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann. Intern. Med. 116: 273-278 (1992) 6. Jackson L.A., Campell L.A., Schmidt R.A., Kuo C.C., Cappuccio A.L., Lee M.J., Grayston J.T.: Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am. J. Pathol. 150: 1785-1790 (1997) 7. Jantos C.A., Nesseler A., Waas W., Baumgartner W., Tillmanns H., Haberbosch W.: Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease. Clin. Infect. Dis. 28: 988-992 (1999) 8. Weiss S.M., Roblin P.M., Gaydow C.A., , Cummings P., Patton D.L., Schulhoff N.: Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J. Infect. Dis. 173: 957-962 (1996) 9. Gupta S., Leatham E.W., Carrington D., Mendall M.A., Kaski J.C., Camm A.J.: Elevated Chlamydia pneumonia antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96: 404-407 (1997) 10. Gurfinkel E., Bozovich G., Daroca A., Beck E., Mautner B., for the ROXIS Study Group: Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 350: 404-407 (1995) 11. Schussheim A.E., Fuster V.: Antibiotics for myocardial infarction? A possible role of infection in atherogenesis and acute coronary syndromes. Drugs 57: 283-291 (1999) 12. Anderson J.L., Muhlestein J.B.: The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia). J. Infect. Dis. 181(Suppl.): S569-571 (2000) 13. van der Ven A.J., Hommels M.J., Kroon A.A., Kessels A., Flobbe K, van Engelshoven J,, Bruggeman C.A., de Leeuw P.W.: Chlamydia pneumoniae seropositivity and systemic and renovascular atherosclerotic disease. Arch. Intern. Med. 162: 786-790 (1002) 14. Muhlestein J.B., Anderson J.L., Hammond E.H., Zhao L., Trehan S., Schwobe E.P.: Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97: 633-636 (1998) 15. Melissano G., Blasi F., Esposito G., Tarsia P., Dordoni L., Arosio C.: Chlamydia pneumoniae eradication from carotid plaques; Results of an open, randomised treatment study. Eur. J. Vasc. Endovas. Surg. 18: 355-359 (1999) 16. Carlsson J., Miketic S., Mueller K.H., Brom J., Ross R., von Essen R., Tebbe U.: Prior Cytomegalovirus or Chlamydia pneumoniae infection and risk of restenosis after percutaneous transluminal coronary angioplasty. Lancet 350: 1225-1231 (1997) 17. Blasi F., Cosentini R.: Laboratory diagnosis. In: (Allegra L., Blasi F., eds) Chlamydia neumoniae infection. Pp. 10-14, Springer, Milan, 1995 18. Linnanmaki E., Leinonen M., Mattila K., Nieminen M., Valtonen V., Saikku P.: Chlamydia pneunoniae – Specific circulation immune complexes in patients with chronic coronary heart disease. Circulation 87: 1130-1134 (1993) 19. Saikku P., Mattila K., Nieminen M.S., Ekman M.R., Nieminen M.S., Makela P.H., Huttunen J.K., Valtonen V.: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 314: 983-985 (1998) 20. Leatham E.W., Bath P.M., Tooze J.A., Camm A.J.: Increased monocyte tissue factor expression in coronary disease. Br. Heart J. 73: 10-13 (1995) 21. Davies M.G., Hagen P.O.: The vascular endothelium. A new horizon. Surgery 218: 593-609 (1993) 22. Gaydos C.A., Summersgill J.T., Sahney N.N., Ramirez J.A., Quinn T.C.: Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect. Immunity 64: 1614-1620 (1996) 23. Smith D., Gupta S., Kaski J.C.: Chronic Infections and Coronary Heart Disease. Int J Clin Pract. 53: 460-466 (1999) 24. Barath P., Fishbein M.C., Cao J., Berenson J., Helfant R.H., Forrester J.S.: Detection and localization of tumor necrosis factor in human atheroma. Am. J. Cardiol. 65: 297-302 (1990) 25. Kuo C.C., Grayston J.T.: A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumonia strain TWAR. J. Infect. Dis. 162: 755-758 (1990) 26. Krausse R., Leiendecker J., Herrmann G., Harder T., Ullmann U.: Chlamydia pneumoniae infection and restenosis in patients with coronary heart disease. Infection 31: 149-154 (2003) 27. Schiele F., Batur M.K., Seronde M.F., Meneveau N., Sewoke P., Bassignot A., Couetdic G., Caulfield F., Bassand J.P.: Cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori IgG antibodies and restenosis after stent. Heart 85: 304-311 (2001) 28. Neumann F., Kastrati A., Miethke T., et al.: Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointimal proliferation after coronary stent placement (ISAR-3): a randomized, double-blind, placebocontrolled trial. Lancet 357: 2085-2089 (2001) 29. Carlsson J., Miketic S., Brom J., Ross R., Bachmann H., Tebbe U.: Prior Cytomegalovirus, Chlamydia pneumonia or Helicobacter pylori infection and the risk of restenosis after percutaneous transluminal coronary angioplasty. Int. J. Cardiol. 73: 165-171 (2000) 30. Hayashida K., Tanaka M., Moriata H, Hayashi F., Inada T., Suzuki H., Sakamoto T., Katsuragawa M., Hibino H., Kambara H.: Chlamydia pneumoniae seropositivity predicts the risk of restenosis after percutaneous transluminal coronary angioplasty. Heart Vessels 16: 137-45 (2002) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2009 – ANNUAL SUBSCRIPTION 2009 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|